Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H2 2016, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under ... Before It's News, 2 weeks ago
The problem is that clinical trials need a control group, but you can't ethically deny patients with wet AMD anti-VEGF for possibly a 5-year duration, since we know the treatments halt wet progression and even restore vision in some cases. That is ...Eye World, 2 weeks ago
Dry eye, glaucoma, AMD specialists could receive new weapons. By Karen Blum, contributing editor A fter a serious lull in novel eye pharmaceutical development, ophthalmologists are hopeful about encouraging clinical trial results and possible ...Ophthalmology Management, 1 month ago
on your WebpageAdd Widget >Get your members hooked!